Volume 22, Number 11—November 2016
Letter
HIV/Hepatitis C Virus Co-infection among Adults Beginning Antiretroviral Therapy, Malawi
Table
Characteristics of HIV-positive adults with HIV/HCV co-infection, Malawi*
Characteristic | HIV-positive and HCV antibody–negative patients, n = 222 | HIV-positive and HCV-antibody–positive patients, n = 5 |
---|---|---|
Age, y | 36.1 (30.5–41.5) | 34.5 (24.8–50.2) |
Sex, M/F | 88/134 (40/60) | 2/3 (40/60) |
Weight, kg, n = 167 | 59.1 (52.7–66.7) | 59.6 (55.9–68.7) |
Height, cm, n = 170 | 157.0 (151.0–165.0) | 159.5 (151.0–167.0) |
Quantitative HIV RNA [<40] × 103, copies/mL, n = 205 | 44.43 (12.09–158.96) | 30.87 (21.14–95.38) |
History of blood transfusion | 21 (9) | 1(20) |
History of jaundice | 2 (1) | 0 |
eGFR mL/min/1,73 qm, n = 194 | 96.0 (79.0–110.0) | 91.0 (88.0–94.0) |
ALT [7–35], IU/L, n = 183 | 23.3 (14.9–33.4) | 15.6 (13.2–22.5) |
AST [≤38], IU/L, n = 183 | 31.7 (23.0–42.4) | 31.9 (23.2–43.7) |
Total bilirubin level [≤1.3], mg/dL, n = 185 | 0.30 (0.20–0.45) | 0.26 (0.20–0.48) |
Platelet count [122–330] × 109/L, n = 214 | 226 (181–293) | 283 (160–320) |
Hemoglobin level [10.9–17.3], g/dL, n = 215 | 12.4 (10.8–13.7) | 13.3 (11.8–15.1) |
Leukocyte count [2,800–8,400], cells/µL, n = 213 | 4,400 (3,500–5,400) | 3,900 (2,700–6,600) |
CD4 cell count, cells/µL, n = 139 | 284 (101–421) | 319 (189–449) |
*Values are given as total no. (%) or as median with interquartile range for the HCV antibody–negative study population and median with range for the HCV antibody–positive study population, respectively. Reference values are given in brackets. Number of missing values for the HCV-antibody negative patients ranged from 88 to 3, indicated by differing patient numbers in stub column. ALT, alaninine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus.
Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.